Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press112510.17650/1726-9776-2007-3-3-68-72DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыMonitoring of PSA changes and assessment of the diagnostic value of PSA growth rates in patients with prostate cancer after radical prostatectomyМониторинг динамики ПСА и оценка диагностической ценности скорости прироста ПСА у больных раком предстательной железы после радикальной простатэктомииPyanykhP. P.ПьяныхП. П.
Russian Federation
VorobyevN. V.ВоробьевН. В.
Russian Federation
NyushkoK. M.НюшкоК. М.
Russian Federation
P.A. Herzen Moscow Research Oncological InstituteМосковский научно-исследовательский онкологический институт им. П.А. Герцена300920073368721602202016022020https://oncourology.abvpress.ru/oncur/article/view/1125

Objective. To define the prognostic value of the growth rate (GR) in the level of prostate-specific antigen (PSA) after radical prostatectomy (RPE).

Materials and methods. The data on 48 patients who underwent RPE in 1999—2006, in whom a biochemical recurrence was verified on the basis of the results of PSA monitoring, were retrospectively analyzed. PSA GR was calculated for each patient. Correlation analysis using the major predictors was also made.

Results. During a follow-up, overall and tumor-specific survivals were 91,7 and 93,8%, respectively. Five-year relapse-free survival calculated by the Kaplan-Meier method was 67%. PSA GR proved to be an independent predictor of relapse-free survival. Generalization was more common at a PSA GR of > 2 ng/ml/year while a PSA GR of 1,0—2,0 ng/ml/year is more typical of the development of a localized recurrence.

Conclusion. Analysis of post-PRE PSA GR makes it possible to predict the postoperative course of prostate cancer, to reveal its early progression, and to perform therapy in due time. For early diagnosis of its clinical progression, it is expedient to assess a combination of predictors, by making up progression-risk groups.

.

1. Злокачественные новообразования в России в 2004 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.; 2006. с. 98.Злокачественные новообразования в России в 2004 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.; 2006. с. 98.2. D'Amico A., Chen M., Roehl K. et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Eng J Med 2004;351:125—35.D'Amico A., Chen M., Roehl K. et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Eng J Med 2004;351:125—35.3. D'Amico A., Moul J., Carroll P. et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004:172:S42—S47.D'Amico A., Moul J., Carroll P. et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004:172:S42—S47.4. Daskivich T.J., Kantoff W.K. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. J Clin Oncol 2006;24(18 Suppl):4616.Daskivich T.J., Kantoff W.K. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. J Clin Oncol 2006;24(18 Suppl):4616.5. Sengupta S., Myers R., Slezak J. et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005:174:2191—6.Sengupta S., Myers R., Slezak J. et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005:174:2191—6.6. Roberts S., Blute М.L., Bergstralh E.J. et al. Скорость прироста и время удвоения ПСА как предсказатель клинической прогрессии после РПЭ. Urology (S.G.R., M.L.B., H.Z.) и Раздел Biostatistics (E.J.B., J.M.S.), Mayo Клиника, Rochester, Minn. Отдел Urology, Mayo Клиника, Rochester, MN 55905.Roberts S., Blute М.L., Bergstralh E.J. et al. Скорость прироста и время удвоения ПСА как предсказатель клинической прогрессии после РПЭ. Urology (S.G.R., M.L.B., H.Z.) и Раздел Biostatistics (E.J.B., J.M.S.), Mayo Клиника, Rochester, Minn. Отдел Urology, Mayo Клиника, Rochester, MN 55905.7. Zagars G., Pollock A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997:44:213—21.Zagars G., Pollock A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997:44:213—21.8. Lam J.S., Belldegrun A.S. Using PSA kinetics to stratify risk of prostate cancer progression. Source: Urology Times. Originally published: September 1, 2005.Lam J.S., Belldegrun A.S. Using PSA kinetics to stratify risk of prostate cancer progression. Source: Urology Times. Originally published: September 1, 2005.9. Dotan Z.A., Bianco F.I. Jr., Rabbani F. et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23(9):1962—8.Dotan Z.A., Bianco F.I. Jr., Rabbani F. et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23(9):1962—8.10. Алексеев Б.Я. Лечение локализованного и местно-распространенного РПЖ. Автореф. дис. … докт. мед. наук. М.; 2006.Алексеев Б.Я. Лечение локализованного и местно-распространенного РПЖ. Автореф. дис. … докт. мед. наук. М.; 2006.